Enzo Reaches Marketing Deal for IncellDx's HPV Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem announced today that its Enzo Clinical Labs subsidiary has reached a deal to market a test based on IncellDx's HPV OncoTect technology.

HPV OncoTect will be validated in-house at Enzo Clinical labs, after which the company will seek approval in New York State to market the assay as a laboratory-developed test. If approved, Enzo would become the first New York licensed reference lab offering the test, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.